Moreover, combination treatment of sorafenib and sulfasalazine significantly reduced BCAT2 in protein- and mRNA-expression levels (Figs. S14A and S14B), diminished GSH level (Fig. S14C), and augmented MDA level (Fig. S14D) in the orthotopic HCC tissues. The gene discussed is BCAT2; the disease is hepatocellular carcinoma.